Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

RTTNews | Pred 424 dňami

(RTTNews) - Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. (SGEN) and Astellas Pharma Inc. (ALPMY.PK, ALPMY).

The trial evaluated KEYTRUDA, Merck's anti-PD-1 therapy, in combination with Padcev versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

In the trial, KEYTRUDA in combination with enfortumab vedotin met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement versus chemotherapy in patients with previously untreated la/mUC.

The trial enrolled patients who may or may not be eligible for treatment with cisplatin-based chemotherapy, regardless of PD-L1 status.

The combination also showed a statistically significant improvement in overall response rate (ORR), a key secondary endpoint, versus chemotherapy. The safety profile of KEYTRUDA and enfortumab vedotin in this study was consistent with previously reported studies of this combination.

The Phase 3 KEYNOTE-A39 trial is intended to serve as the confirmatory trial for the current U.S. accelerated approval of KEYTRUDA in combination with enfortumab vedotin.

For More Such Health News, visit rttnews.com

Merck Q2 Results Top Estimates, But Slashes FY24 Earnings Outlook

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the second quarter compared to a loss last year, reflecting improved gross margins and a 7 percent sales growth. Both adjusted earnings per share and quarterly sales topped analysts' estimates. However, the company slashed its adjusted earnings guidance for the full-year 2024.

RTTNews | Pred 112 dňami

Ligand Says Merck Receives FDA Approval For CAPVAXIVE For Adults

Ligand Pharmaceuticals Inc. (LGND) announced Tuesday that its collaborator Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE, previously known as V116, a 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population.

RTTNews | Pred 154 dňami

Merck Begins Phase 3 Trial Of MK-1084 As First-Line Treatment Of Certain Metastatic NSCLC Patients

Merck & Co. Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Thursday it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1.

RTTNews | Pred 229 dňami

Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.

RTTNews | Pred 242 dňami

Merck Says Health Canada Oks KEYTRUDA In Combination With Trastuzumab And Chemotherapy

Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, announced Monday that Health Canada has granted approval of KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors express PD-L1 as determined by a validated test.

RTTNews | Pred 281 dňami

Merck Guides FY24 EPS Above Estimates As Q4 Results Top Estimates

Biopharmaceutical company Merck reported Thursday a net loss for the fourth quarter compared to a profit last year, hurt by hefty charge, despite 6 percent sales growth. However, both adjusted earnings per share and quarterly sales topped analysts' estimates.

RTTNews | Pred 292 dňami

Merck Q4 Results Top Estimates; Guides FY24 Adj. EPS Above Estimates

Biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, reported Thursday a net loss attributable to the company for the fourth quarter of $1.23 billion or $0.48 per share, compared to net income of $3.02 billion or $1.18 per share in the prior-year quarter.

RTTNews | Pred 292 dňami

Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck & Co. Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.

RTTNews | Pred 333 dňami

EURUSD	1.0586	GBPUSD	1.2649	AUDUSD	0.65119
USDJPY	154.087	USDCAD	1.39883	USDCHF	0.88195